Immunic, inc. strengthens its board of directors with the appointment of richard rudick, m.d.

– thought-leader in multiple sclerosis with decades of experience in academic medicine and the pharmaceutical industry – new york , april 27, 2023 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of richard rudick, m.d., a thought-leader in multiple sclerosis with decades of experience in the clinic, academia and industry, to its board of directors, effective april 26, 2023.
IMUX Ratings Summary
IMUX Quant Ranking